Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M05D1 vs Investigator's Choice in CLDN18.2+ Advanced Gastric/GEJ Cancer
NCT07518147Phase 3Recruiting
- Sponsor
- Sichuan Biokin Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M05D1 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Sichuan Biokin Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
BL-M05D1
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07518147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518147.